Isogenica develops and licenses advanced synthetic antibody libraries and display technologies, enabling its partners to accelerate their therapeutic antibody discovery programs.
Our well-established llamdA™ camelid single domain antibody library and our novel human Fab antibody library have been constructed using proprietary Colibra™ DNA library building technology. This ensures the highest possible fidelity to the library design, but also allows for removal of CMC liability motifs from hypervariable regions. Combined with the high and unbiased diversity encoded in the synthetic library, this ensures our licensees can isolate liability free therapeutic antibodies in a minimal timeframe without needing extensive downstream antibody optimization.
The full diversity of our libraries exceeds the capacity of mainstay display technologies, including phage display. Isogenica therefore provides CIS Display, a proprietary cell-free DNA-based in vitro
display technology to select repertoires of 1012
and beyond. Use of this synthetic biology method throughout selection and screening stages ensures extremely fast hit identification and lead characterization timelines, and enables the miniaturized ultrahigh throughput screening required to isolate rare antibodies meeting stringent criteria.